Dyslipidemia & Statins for NEET PG 2026: Lipid Targets, ASCVD Risk, Therapy

Cardiovascular disease is now the leading cause of death in India, and atherogenic dyslipidemia is the single most modifiable driver. NEET PG examiners blend the biochemistry of lipid transport with the clinical decisions around statin intensity, residual-risk add-ons, and primary versus secondary prevention. The 2019 ESC/EAS dyslipidemia guideline and the 2022 ACC focused update redrew the LDL targets, and the 2023 introduction of inclisiran (twice-yearly siRNA) changed the long-term adherence picture.

This NEETPGAI deep dive walks through lipid metabolism, fasting profile interpretation, ASCVD risk stratification, the modern stepped pharmacotherapy ladder, and the India-specific epidemiology that makes premature CAD so common in young Indian men. Pair this guide with the heart failure deep dive and the antiplatelet and anticoagulant guide for full preventive-cardiology coverage.

Lipid metabolism in 90 seconds

NEET PG vignettes routinely ask which apolipoprotein binds which receptor, so memorize the trio:

• Exogenous pathway — dietary fat is packaged into chylomicrons (ApoB-48 from intestine), hydrolysed by lipoprotein lipase (LPL, activated by ApoC-II), and remnants are cleared by hepatic ApoE receptors.
• Endogenous pathway — liver releases VLDL (ApoB-100) which becomes IDL then LDL via LPL and hepatic lipase. LDL is cleared by hepatic LDL receptors that recognise ApoB-100.
• Reverse cholesterol transport — HDL (ApoA-I) picks up free cholesterol from peripheral tissues via ABCA1, esterifies it via LCAT, and returns it to the liver via SR-B1.

Examiner-favourite enzyme deficiencies: LPL deficiency (Type I hyperlipoproteinaemia, eruptive xanthomas, milky plasma) and familial hypercholesterolaemia (LDL receptor mutation; tendon xanthomas; LDL above 190 mg/dL in adults or above 160 mg/dL in children).

Classification of dyslipidemia

Primary (genetic) dyslipidemias

Secondary dyslipidemia

Common causes: diabetes mellitus (atherogenic pattern with low HDL and high triglycerides), hypothyroidism (high LDL, can be a reversible cause of statin-resistant LDL), nephrotic syndrome (high LDL and Lp(a)), chronic kidney disease, cholestasis, alcohol (high triglycerides), oral oestrogens, thiazides, beta-blockers (mild), retinoids, and protease inhibitors.

The fasting lipid profile and modern targets

A standard fasting profile (9 to 12 hours) reports total cholesterol, HDL, triglycerides, and a calculated LDL via the Friedewald formula: LDL = TC minus HDL minus (TG divided by 5). The formula is unreliable when triglycerides exceed 400 mg/dL — use direct LDL or non-HDL.

Non-HDL cholesterol equals total cholesterol minus HDL and captures every atherogenic apoB particle. It does not require a fasting sample and is the preferred metric in patients with metabolic syndrome or triglycerides above 200 mg/dL.

ApoB measures every atherogenic particle on a one-to-one basis (LDL, IDL, VLDL, Lp(a), chylomicron remnants) and is the most accurate single marker of cardiovascular risk in people with diabetes, metabolic syndrome, or discordant LDL.

LDL goals by risk category (2019 ESC/EAS, 2022 ACC consensus)

Note that triglycerides are a marker, not a target — fibrate-induced triglyceride lowering does not reduce ASCVD events unless triglycerides are above 200 mg/dL with high non-HDL.

ASCVD risk calculation

The 2018 ACC/AHA Pooled Cohort Equations remain the global standard, estimating 10-year ASCVD risk from age, sex, race, total cholesterol, HDL, systolic BP, treatment for hypertension, smoking, and diabetes. Output thresholds drive primary-prevention therapy:

• 10-year risk under 5 percent — lifestyle.
• 5 to 7.5 percent — selectively offer moderate-intensity statin if risk-enhancers present.
• 7.5 to 19.9 percent — moderate-intensity statin recommended.
• 20 percent or above — high-intensity statin recommended.

Risk-enhancing factors that upgrade borderline patients: family history of premature ASCVD, persistent LDL above 160 mg/dL, metabolic syndrome, CKD, chronic inflammation (psoriasis, RA, HIV), South Asian ancestry, premature menopause, pre-eclampsia history, ApoB above 130 mg/dL, Lp(a) above 50 mg/dL, and CAC score above 100 Agatston units.

Pharmacotherapy ladder

Step 1 — Statins (HMG-CoA reductase inhibitors)

Statins reduce hepatic cholesterol synthesis, upregulate LDL receptors, reduce LDL by 30 to 55 percent, and have pleiotropic plaque-stabilising effects.

Adverse effects:

• Myalgia and myopathy — 5 to 10 percent on starting therapy. Stratify with CK: under 4 times upper limit allows rechallenge; above 10 times upper limit demands stop and rule out rhabdomyolysis.
• Rhabdomyolysis — rare (less than 0.1 percent), risk highest with simvastatin 80 mg, drug interactions (macrolides, azoles, fibrates especially gemfibrozil, cyclosporine, grapefruit juice).
• Hepatotoxicity — transaminitis above three times upper limit in 1 to 2 percent; routine LFT screening is no longer recommended unless symptomatic.
• New-onset diabetes — 9 percent relative risk increase, but cardiovascular benefit far outweighs the diabetes signal.
• Statin-induced necrotising autoimmune myositis — anti-HMGCR antibody positive, persistent weakness despite stopping the statin, requires immunosuppression.

Step 2 — Ezetimibe

Inhibits NPC1L1 cholesterol transporter at the brush border, reduces intestinal cholesterol absorption, lowers LDL by 15 to 25 percent on top of statin (IMPROVE-IT). First add-on when LDL goal is missed.

Step 3 — PCSK9 inhibitors

PCSK9 normally degrades LDL receptors. Blocking it preserves receptor recycling and dramatically lowers LDL.

• Monoclonal antibodies — alirocumab and evolocumab subcut every 2 weeks, LDL reduction 50 to 60 percent on top of statin (FOURIER, ODYSSEY OUTCOMES). Indicated in very high-risk ASCVD or HeFH despite max-tolerated statin and ezetimibe.
• Inclisiran — siRNA against hepatic PCSK9 mRNA, 284 mg subcut every 6 months after a loading dose at 0 and 3 months (ORION trials). Preferred for adherence.

Step 4 — Bempedoic acid

ATP citrate lyase inhibitor upstream of HMG-CoA reductase. Reduces LDL by 18 percent. Useful in statin-intolerant patients (CLEAR Outcomes trial confirmed CV benefit). Watch for hyperuricaemia and tendon rupture.

Triglyceride-targeted therapy

Reserved for triglycerides above 500 mg/dL (acute pancreatitis prevention) or above 150 mg/dL with established ASCVD on statin (residual-risk reduction).

• Fibrates — fenofibrate is the safer choice; gemfibrozil interacts with statins and worsens rhabdomyolysis risk. PPAR-alpha agonists, lower triglycerides 30 to 50 percent.
• Omega-3 fatty acids (icosapent ethyl) — REDUCE-IT showed 25 percent ASCVD reduction at 4 g/day in patients with triglycerides 135 to 499 mg/dL on statin. Combined EPA plus DHA preparations did NOT show similar benefit (STRENGTH).
• Niacin — historically used; AIM-HIGH and HPS2-THRIVE showed no incremental benefit on top of statin and increased adverse events. Avoid for ASCVD outcomes.

Bile acid sequestrants

Cholestyramine, colesevelam, colestipol bind bile acids in the gut, reducing enterohepatic circulation. Lower LDL by 15 to 30 percent. Niche role today; useful in pregnancy because they are not absorbed. Watch for raised triglycerides, constipation, and reduced absorption of fat-soluble vitamins and warfarin.

Primary versus secondary prevention thresholds

Primary prevention:

• Age 40 to 75 with diabetes — moderate-intensity statin regardless of LDL.
• Age 40 to 75 with LDL above 70 mg/dL and 10-year ASCVD risk above 7.5 percent — moderate-intensity statin.
• LDL 190 mg/dL or above at any age (likely FH) — high-intensity statin without need for risk calculator.
• Age 20 to 39 with risk-enhancers (family history, persistent high LDL, metabolic syndrome) — selective statin therapy.

Secondary prevention:

• Any established ASCVD (post-MI, post-stroke, peripheral artery disease, prior revascularisation) — high-intensity statin to reach LDL under 70 mg/dL, with 55 mg/dL target if very high-risk.
• Statin intolerance — moderate intensity plus ezetimibe; add PCSK9 inhibitor or inclisiran early.

NEET PG MCQ traps

1. Friedewald breakdown — formula is invalid above triglycerides of 400 mg/dL; use direct LDL or non-HDL.
2. Statin plus gemfibrozil — rhabdomyolysis risk; choose fenofibrate when combination is needed.
3. Hypothyroidism unmasking — statin-resistant high LDL in a patient with weight gain and constipation is hypothyroidism until proved otherwise.
4. Ezetimibe before PCSK9 — examiner stem will offer "next step" with LDL still above goal on max statin; ezetimibe is first add-on, not PCSK9.
5. Lp(a) — measure once in lifetime; statins do not lower it; PCSK9 inhibitors lower it modestly; aspirin and lifestyle do not.
6. Familial hypercholesterolaemia — Dutch Lipid Network or Simon Broome criteria; tendon xanthomas, family history of premature CAD, LDL of 190 mg/dL or above. Cascade screen first-degree relatives.
7. Statin in pregnancy — Category X historically; recent FDA removed the contraindication in 2021, but most guidelines still avoid statins during pregnancy and breastfeeding. Use bile-acid sequestrants for severe FH.
8. Severe hypertriglyceridemia and pancreatitis — admit, IV fluids, insulin infusion (if diabetic), heparin (mobilises LPL), apheresis if above 1000 mg/dL with organ failure.
9. Eruptive xanthomas with milky serum — Type I or V hyperlipoproteinaemia. The specimen sits in the centrifuge with a creamy supernatant.
10. Anti-HMGCR myopathy — unlike simple statin myalgia, this autoimmune syndrome persists after statin withdrawal and needs steroids.

Recent updates and Indian context

• 2019 ESC/EAS dyslipidemia guideline — the LDL under 55 mg/dL target for very high-risk ASCVD became standard.
• 2022 ACC consensus pathway — lipid-lowering decision-tree integrates ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran.
• REDUCE-IT (icosapent ethyl) — 4 g/day cut major adverse cardiovascular events 25 percent in statin-treated patients with elevated triglycerides.
• CLEAR Outcomes (bempedoic acid) — 13 percent MACE reduction in statin-intolerant patients (2023).
• Inclisiran — twice-yearly siRNA approved in India in 2023, addressing the chronic adherence problem with monthly injections.
• INTERHEART India arm — Indians have heart attacks 8 to 10 years earlier than Caucasians; central obesity (waist circumference above 90 cm in men, above 80 cm in women), atherogenic dyslipidemia (low HDL, high triglycerides, small dense LDL), tobacco use, and diabetes account for 90 percent of the incidence.
• Lipid Association of India (LAI) 2020 statement — recommends LDL under 50 mg/dL for "extreme risk" Indian patients (FH plus ASCVD; recurrent ACS within 1 year; ASCVD plus diabetes plus low HDL).
• NMC and FMGE alignment — Indian undergraduate exams emphasise ApoB and Lp(a) cutoffs and the use of fenofibrate over gemfibrozil with statins in metabolic syndrome.

Frequently asked questions

What LDL target is recommended for very high-risk ASCVD patients?

For very high-risk patients (established ASCVD with recurrent events, multivessel disease, or familial hypercholesterolaemia), the 2019 ESC/EAS and 2022 ACC consensus recommend an LDL goal below 55 mg/dL, with a minimum 50 percent reduction from baseline. High-risk patients aim for under 70 mg/dL, and primary prevention with diabetes plus risk factors targets under 100 mg/dL.

Which statins are high-intensity?

High-intensity statins lower LDL by at least 50 percent. The two regimens that qualify are atorvastatin 40 to 80 mg daily and rosuvastatin 20 to 40 mg daily. Moderate-intensity statins (LDL reduction 30 to 49 percent) include atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, and pravastatin 40 to 80 mg.

When should PCSK9 inhibitors be added?

PCSK9 inhibitors (alirocumab, evolocumab, inclisiran) are added when LDL stays above goal despite maximum-tolerated statin plus ezetimibe in very high-risk ASCVD or heterozygous familial hypercholesterolaemia. They reduce LDL by 50 to 60 percent on top of statin therapy. Indian access is limited by cost, with inclisiran administered every six months giving better adherence.

How do you investigate suspected statin myopathy?

Stop the statin, measure CK and creatinine, and rule out hypothyroidism, vitamin D deficiency, drug interactions, and hard exercise. Mild myalgia with CK below 4 times upper limit can be re-challenged with a different statin. CK above 10 times upper limit, rhabdomyolysis, or true autoimmune statin-induced necrotising myopathy (anti-HMGCR antibody) requires permanent discontinuation.

Why is the INTERHEART data important for India?

INTERHEART showed that nine modifiable risk factors account for over 90 percent of myocardial infarctions globally, with apolipoprotein ratio (ApoB:ApoA1), smoking, hypertension, and diabetes the strongest. Indians had MIs almost a decade earlier than Western populations, with central obesity and atherogenic dyslipidemia (low HDL, high triglycerides, small dense LDL) driving premature ASCVD.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: May 2026